AC-101
Ulcerative Colitis / Inflammatory Bowel Disease
Phase 1bActive; FDA clearance for Phase II MRCT
Key Facts
Indication
Ulcerative Colitis / Inflammatory Bowel Disease
Phase
Phase 1b
Status
Active; FDA clearance for Phase II MRCT
Company
About Accro Bioscience
Clinical-stage biotech developing novel therapeutics targeting regulated cell death mechanisms for immune-mediated diseases and cancer.
View full company profile